Stephen Gottschalk Selected Research

Chimeric Antigen Receptors

11/2022	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
10/2022	CAR T cell therapy for solid tumors: Fatal attraction requires adhesion.
1/2022	Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells.
1/2022	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
1/2022	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
1/2022	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
11/2021	Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
11/2021	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
11/2021	Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity.
1/2021	Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen Gottschalk Research Topics

Disease

85	Neoplasms (Cancer) 10/2022 - 01/2002
12	Hematologic Neoplasms (Hematological Malignancy) 10/2022 - 04/2011
11	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 11/2008
11	Glioma (Gliomas) 01/2022 - 03/2011
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2016
11	Glioblastoma (Glioblastoma Multiforme) 06/2018 - 03/2013
8	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2002
8	Infections 01/2022 - 09/2011
8	Lymphoma (Lymphomas) 11/2018 - 05/2006
6	Leukemia 01/2022 - 09/2011
6	Osteosarcoma (Osteogenic Sarcoma) 01/2021 - 10/2009
5	Virus Diseases (Viral Diseases) 11/2021 - 09/2011
5	Brain Neoplasms (Brain Tumor) 01/2021 - 03/2011
5	Nasopharyngeal Carcinoma 01/2019 - 07/2007
4	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2015
4	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 03/2013
4	Bites and Stings (Sting) 01/2021 - 01/2016
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2018 - 01/2005
3	Breast Neoplasms (Breast Cancer) 11/2021 - 06/2007
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 03/2014
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 01/2022
2	Communicable Diseases (Infectious Diseases) 01/2022 - 05/2009
2	Lymphopenia (Lymphocytopenia) 01/2022 - 03/2009
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 01/2021
2	Human Influenza (Influenza) 01/2020 - 08/2012
2	Head and Neck Neoplasms (Head and Neck Cancer) 11/2017 - 08/2011
2	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2008 - 12/2006
1	Neuroblastoma 01/2022
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020
1	Paramyxoviridae Infections (Parainfluenza) 01/2020
1	X-Linked Combined Immunodeficiency Diseases (X Linked Severe Combined Immunodeficiency) 01/2019
1	Pathologic Complete Response 11/2018
1	Multiple Myeloma 01/2018
1	Persistent Infection 12/2017

Drug/Important Bio-Agent (IBA)

52	Chimeric Antigen ReceptorsIBA 11/2022 - 06/2007
49	AntigensIBA 01/2022 - 03/2003
12	CytokinesIBA 01/2020 - 01/2002
9	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2002
8	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019 - 05/2006
8	Proteins (Proteins, Gene)FDA Link 10/2017 - 03/2003
5	human ERBB2 proteinIBA 05/2015 - 06/2007
5	VaccinesIBA 08/2013 - 02/2007
4	Erythropoietin FDA Link 01/2021 - 03/2013
4	Monoclonal AntibodiesIBA 09/2020 - 03/2005
4	Antiviral Agents (Antivirals)IBA 10/2019 - 09/2011
4	EpitopesIBA 01/2019 - 05/2006
4	Interleukin-2 (IL2)IBA 09/2017 - 06/2007
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2022
3	InterleukinsIBA 01/2020 - 03/2013
3	Pharmaceutical PreparationsIBA 10/2019 - 11/2017
3	Viral AntigensIBA 01/2015 - 10/2007
2	tisagenlecleucelIBA 01/2022 - 01/2022
2	SurvivinIBA 01/2022 - 01/2022
2	AntibodiesIBA 01/2022 - 03/2011
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 04/2021
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 08/2013
2	Peptides (Polypeptides)IBA 01/2022 - 01/2018
2	CD19-specific chimeric antigen receptorIBA 01/2022 - 01/2022
2	LigandsIBA 11/2021 - 03/2005
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2018 - 12/2017
2	Bispecific AntibodiesIBA 01/2018 - 04/2015
2	InterferonsIBA 09/2017 - 03/2013
1	CD19 AntigensIBA 01/2022
1	HLA-A Antigens (HLA-A)IBA 01/2022
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2022
1	fludarabineIBA 01/2022
1	DNA Methyltransferase 3AIBA 11/2021
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 11/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021
1	Mucin-1 (CA 15-3 Antigen)IBA 11/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	EphA2 ReceptorIBA 01/2021
1	Fibronectins (Fibronectin)IBA 01/2021
1	CollagenIBA 01/2021
1	Interleukin-12 (IL 12)IBA 01/2020
1	TEMPOIBA 01/2020
1	EBV-encoded nuclear antigen 1IBA 01/2019
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2018
1	blinatumomabIBA 01/2018
1	Single-Chain AntibodiesIBA 01/2018
1	Interleukin-7 (Interleukin 7)IBA 11/2017

Therapy/Procedure

43	Therapeutics 10/2022 - 01/2002
39	Immunotherapy 01/2022 - 03/2005
11	Hematopoietic Stem Cell Transplantation 01/2021 - 01/2002
8	Drug Therapy (Chemotherapy) 01/2022 - 07/2007
5	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 08/2011
4	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/2018 - 05/2006
3	Transplantation 11/2018 - 11/2008
3	Stem Cell Transplantation 04/2013 - 12/2006
2	Cell Transplantation 01/2021 - 01/2020
1	Combined Modality Therapy 01/2021
1	Surgical Amputation (Amputations) 01/2021
1	Injections 11/2017